Reported Sep 14, 2016 · Terminated

Bromocriptine Mesylate Capsules USP, 5 mg, 30-count bottles, Rx only, Manufactured by: Cadila Healthcare ltd.,…

Zydus Pharmaceuticals USA Inc.

Moderate riskThis product could cause temporary or reversible health problems — stop using it.

What you should do

Stop using the affected lot and contact the recalling firm for the return or refund process. Check the FDA enforcement report for lot-level detail.

Firm contact: Zydus Pharmaceuticals USA Inc · 73 Route 31 N · Pennington, NJ · 08534-3601

Is this the product you have?

  • Bromocriptine Mesylate Capsules USP, 5 mg, 30-count bottles, Rx only
  • Manufactured byCadila Healthcare ltd., Ahmedabad
  • India Distributed byZydus Pharmaceuticals USA Inc., Pennington, NJ 08534, NDC 68382-110-06
Lot codes and dates
    • Lot # MP993
    • Exp10/16
    • MR2704
    • Exp 02/17
    • MR6851
    • MR8100
    • Exp 07/17 and MR1210
    • Exp 12/17
Amount recalled
14,808 bottles

Where it was sold

  • Nationwide

Why it was recalled

Failed impurities/degradation specifications: Out of specification results noticed in related substance test during analysis of 24 months long term (25 degree Celsius /65% RH) stability samples of two batches.

This product could cause temporary or reversible health problems — stop using it.

Want the full recall guide?

The guide adds the identifying codes laid out for scanning, symptoms to watch for, a timeline, and news coverage of this recall.

Free recall alerts

Get alerted about new Zydus Pharmaceuticals USA Inc. recalls

One email when a matching recall is published. No account, no cost, unsubscribe in one click.

Where this came from

Source: U.S. Food & Drug Administration (openFDA)

Read the FDA (openFDA drug enforcement) notice

Notice updated May 1, 2018 · Data as of Sep 19, 4:58 PM UTC

RecallNow is not a government agency. Every fact on this page is published by the FDA, USDA or CPSC and links back to their notice.